New England Journal of Medicine · 2020 · 11 citations · 3 references
LawCompetition LawPharmaceutical PolicyDrug Approval ProcessesDrug LawPharmaceutical RegulationDrug EnforcementGeneric Drug Substitution LawPharmaceutical MarketingPrescription Drug OffensesRegulatory ExclusivityRegulatory PharmacologyBuprenorphine RegulationFda Drug RegulationFda RegulationGeneric Drug EntryGeneric Drug MarketingGeneric Drug PricingMarket Entry AssessmentPharmaceutical Market Competition
The manufacturer of brand-name buprenorphine products exploited various FDA regulatory procedures to impede market entry of generic competitors and to maintain high prices. This case provides an example of the kinds of abuses that are common in prescription-drug markets.
3